About

Jeff Mann serves as Senior Vice President, General Counsel and Product Development, prior to which he served as the Senior Vice President, General Counsel and Head of Corporate Development of Diabetes Care at BD until the Separation. Previously, Jeff served as General Counsel and Corporate Secretary of Cantel Medical Corp (Cantel).

Prior to Cantel, Jeff spent 14 years with Boston Scientific Corporation in roles including M&A, venture capital investments, SEC and corporate governance, patent strategy, litigation, and business unit support for the Med Surg group. Jeff also served on the Board of Directors of Preventice Solutions and as Chair of its Compensation Committee. He holds a Bachelor of Science degree in Civil and Environmental Engineering from Lafayette College and a J.D. from Boston College Law School, magna cum laude.

Mr. Mann became Senior Vice President, General Counsel, Head of Corporate Development and Corporate Secretary of Embecta as of the Effective Time of the spin-off from BD on April 1, 2022.

Roles

Embecta Corp.
Senior Vice President, General Counsel and Product Development · Current role
Present
BD (Becton, Dickinson and Company)
Senior Vice President, General Counsel and Head of Corporate Development of Diabetes Care · Served until the Separation.
Cantel Medical Corp
General Counsel and Corporate Secretary
Boston Scientific Corporation
Various roles including M&A, venture capital investments, SEC and corporate governance, patent strategy, litigation and Med Surg business unit support · Spent 14 years.

External Roles

Preventice Solutions
Director

Fixed Compensation

FY 2025
Salary
$600,769
ComponentAnnual base salary
All other compensation
$34,017
Total compensation
$3,005,372

Performance Compensation

Data from FY 2025

Cash incentive

Annual cash incentive
$470,554
FormCash
Target Opportunity
Evaluation periodFY2025

Stock awards

Stock awards
$1,900,032
FormTVUs and PSUs

Also at Embecta Corp.

Related

See how VectorShift works for your firm

Request Demo